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Summary Interleukin-4 receptor (IL-4R) and Epidermal Growth Factor receptor (EGFR) were assessed as
factors associated with adenoma-carcinoma progression in colorectal cancer and tumour invasion. A mono-
clonal antibody (MR6) was applied to detect IL-4R in: metaplastic polyps (five cases), adenomas (15 cases),
and carcinomas (44 adenocarcinomas and one squamous cell). Positive labelling was obtained in all polyps,
adenomas and in 40/45 carcinomas. Normal colonic mucosa of these patients, as well as macrophages and
lymphocytes infiltrating the tumour stroma, were also positively labelled with MR6. Four out of five poorly
differentiated adenocarcinomas did not show IL-4 receptor expression. No significant correlation was found
with tumour size, lymph node stage and IL-4 receptor expression.
On the above specimens a parallel detection of epidermal growth factor receptors (EGFR) by a monoclonal
antibody (EGFR 1) was carried out. Expression of EGFR was found in 14/20 polyps and in 22/45 carcinomas.
All but one of the EGFR positive malignant tumours showed coexpression of IL-4 receptor. Lymph node
involvement by tumour cells was detected in 25 out of 45 patients. Eighteen of these 25 cases were positive
with EGFRI.
Interleukins were first described as a group of signalling
polypeptides, controlling the activity of lymphoid and haem-
opoietic cells, (O'Garra, 1989a,b) but individual members
have now been shown to stimulate other cell types such as
keratinocytes, chondrocytes, fibroblasts (IL-l) and glial cells
of the nervous system (IL-2) (Durum et al., 1985; Benveniste
& Merrill, 1986). In addition interleukins -1 and -6 may
inhibit the growth of breast cancer cells (Gafney & Tsai,
1986).
Interleukin-4 (IL-4) was initially characterized as a B-cell
growth factor, (Howard et al., 1982) but it has also been
shown to exert its effects on T-lymphocytes, granulocytes,
macrophages and some epithelial cell lines (O'Hara & Paul,
1987; Park et al., 1987; Fernandez-Botran et al., 1986; Mos-
mann et al., 1986). It may promote or suppress the maturation
of haemopoietic cells, as progenitor cells respond differently
to IL-4, at different stages of maturation (Rennick et al.,
1987). Direct effects of inhibition or stimulation have been
reported on melanoma cell lines (Mortarini et al., 1990).
The capacity of IL-4 to increase the expression of secretory
component, the epithelial receptor for polymeric Ig, on a
colonic adenocarcinoma cell line, extends the list of effects of
IL-4 and suggests the presence of IL-4 receptors on epithelial
cells (Phillips et al., 1990).
Recently it has been shown in murine tumours that IL-4
displays strong anti-tumour activity in vivo. It is proposed
that localised elaboration of IL-4 (and other lymphokines) as
a normal host response to a putative tumour antigen could
initiate a cascade of events involving the activation of
inflammatory cells and humoral mediators, leading to the
destruction of the tumour cells (Tepper et al., 1989). Anti-
tumour effect was reversed by anti-IL-4 antibody. IL-4 can
also enhance similar effects shown by IL-lb, IL-2 and
interferon gamma (Forni et al., 1989).
In view of the demonstration of IL-4 receptors on epi-
thelial cell lines and IL-4 effects on cell lines, it would be of
value to ascertain whether IL-4 plays any role in the develop-
ment of progression of human cancers, particularly the com-
monest epithelial tumours.
A preliminary study analysed the expression of IL-4 recep-
tors on a small number of malignant tumours including one
case of colon cancer and their normal counterparts. They
found that IL-4R molecules are upregulated in tumours of
epithelial origin and that the antibody used, (MR6) is
effective as an in vivo tumour imaging agent (Al Jabaari et
al., 1989).
The present study was undertaken to provide a detailed
analysis of the distribution of IL4 receptors using a recently
produced monoclonal antibody (MR6) which recognizes an
antigen constantly associated with the receptor (De Maagol
et al., 1985). These results have been compared with labelling
for EGFR in the same series as a control and since there is
already detailed information about the distribution and role
of EGFR in other epithelial neoplasms (Liberman et al.,
1984; Berger et al., 1987; Gullick et al., 1986; Veale et al.,
1989; Perez et al., 1984).
Materials and methods
Tissues
Representative samples of tumour specimens were collected
at resection from 44 patients with primary colon cancer and
one with an anal squamous cell carcinoma. Non-neoplastic
colonic tissue was also separately sampled, at least 5 cm from
the edge of the tumour. Twenty colonic polyps (metaplastic:
five, tubular: nine, villous: six) were also obtained, two by
colonoscopic biopsy and 18 as resection specimens.
All the above tissues were snap frozen in liquid nitrogen
and stored at - 70°C. Histological diagnosis and evaluation
of the differentiation and staging were assessed by light mic-
roscopy before immunohistochemical staining.
Antibodies
The primary antibodies used are summarised below.
Antibody MR6 The monoclonal antibody MR6 was raised
against an extract of thymic tissue and shown to react
strongly with thymic cortical epithelial cells. By Western
blotting MR6 detects a single polypeptide of 200 kD which is
rapidly cleaved to 145 kD by proteolytic enzymes. This latter
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is known to be the approximate molecular weight of one of
the four polypeptide chains associated with the IL4 receptor.
Flow cytometric and immunohistochemical studies showed
the antigen to be present also on T and B lymphocytes, cells
ofmyeloid lineage and some renal epithelium. Recent experi-
ments strongly suggest that MR6 binds to the IL4 receptor
complex by demonstrating that MR6 inihibits IL4 induced T
cell proliferation and completely abrogates the IL4 produc-
tion of specific antigen induced IgE by B cell populations.
MR6 does not however block binding of IL4 to its receptor,
which indicates that it recognises a molecule closely assoc-
iated with the three chains of the IL4-R but which does not
form the ligand binding component of the receptor.
The evidence that MR6 is a reliable marker of IL-4 recep-
tor has been summarised in a previous paper; (Tungekar et
al., 1991) full details of its characteristics have been described
elsewhere (De Maagol et al., 1985; Larche et al., 1988a,
Larche et al., 1988b).
Antibody EGFRI Monoclonal antibody EGFR1 was pro-
duced using cells of the epidermoid carcinoma cell line A431
as immunogen. EGFR1 recognises an antigen of 175,000
mwt which can be specifically cross linked to EGF and
exhibits an EGF-stimulated protein kinase activity
(Waterfield et al., 1982).
Antibody Ki67 All carcinomas, polyps and normal colonic
tissues were also stained with Ki67, (Gerdes et al., 1983) a
monoclonal antibody against a nuclear proliferation-assoc-
iated antigen, to check for viability and antigenic preserva-
tion in the tumour cells at the time of resection.
Immunocytochemistry The antibodies mentioned above were
detected by means of the alkaline phosphatase anti-alkaline
phosphatase (APAAP) method as described previously (Cor-
dell et al., 1984). Briefly 5-81aM acetone fixed sections were
incubated in hybridoma supernatant at room temperature for
a h
d
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Figure 1 a & b: A well differentiated colon cancer shows strong positivity for IL4-R a, but is unstained by EGFR (b). c & d. This
illustrates a metastatic anal squamous cell carcinoma with no labelling for IL4R but strong positivity for EGFR. (d) Positive
lymphocytes at the bottom offigure c. e & f: This figure shows a poorly differentiated adenocarcinoma which is negative for IL4R (e)
but positive for EGFR (f). This tumour constrasts with that shown in a & b.
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30 min. After washing in tris buffered saline rabbit antibody
against mouse immunoglobulins was applied for 15 min. The
sections were then washed and performed APAAP complexes
were added for a further 15-20 min. The last two stages were
repeated before colour development with naphthol AS-BI
phosphate and new fuchsin. All reactions were terminated
after 18-20 min in substrate. For each case a negative con-
trol was included in which the primary antibody was omitted.
Results
Antibody MR6
The main results of this study are summarized in Tables I, II
and III. Positive immunoreactivity for IL-4 receptors was
detected in 40 of 44 colonic adenocarcinomas (Figure 1). The
single anal squamous cell carcinoma was negative (Figure 1).
All of the cases which showed IL-4 receptor expression were
well or moderately differentiated tumours (Table I). Four
poorly differentiated adenocarcinomas showed no labelling.
All polyps (both metaplastic and neoplastic) were stained.
Non-neoplastic colonic mucosa was also positively stained.
The goblet cells showed mainly membranous staining com-
pared to the cells in the crypts where the staining was both
cytoplasmic and membranous.
In the tumour cells the immunostaining was homogeneous
and present in both the cytoplasm and on the cell membrane
and its intensity was much stronger compared to the non-
neoplastic mucosa. In all cases both lymphocytes and macro-
phages infiltrating the tumour stroma were strongly positive
for IL-4 receptor expression (Figure 1).
Antibody EGFRI
Staining for EGF receptors, using the monoclonal antibody
EGFR1, was seen in 22/44 adenocarcinomas and that of the
anal squamous cell carcinoma (Figure 1). Fourteen out of 20
colonic polyps were positively labelled (5/5 metaplastic, 4/6
villous, 5/9 tubular). Detection of staining for EGFR was
detected in normal colonic epithelium in all cases whether or
not the tumour was labelled for EGFR. Labelling was weak
and present mainly in the basal cells of the crypts.
All but one of the adenocarcinomas which showed expres-
sion of EGFR were also positively labelled for IL-4 receptor
(Table II).
Involvement of mesenteric lymph nodes by tumour cells
was seen in 25 out of 45 patients. In eighteen of these 25
cases the primary tumours were EGFR1 positive (Table III).
In only five EGFR1 positive cases could no lymph node
involvement be demonstrated. Seventeen out of 22 negative
cases had no lymph node involvement (Table III and Figure
2). Groups were compared by the chi-square test for cate-
gorical variables (X2 = 9.8, 0.001 <P<0.01, with one degree
of freedom).
Discussion
In this study it has been shown that IL-4 receptors, detected
by the monoclonal antibody MR6, are expressed by more
than 80% of colorectal adenocarcinomas. In 60% of the
IL-4R positive cases there was also coexpression of EGF
receptors.
The maintenance of the expression of IL-4R in colonic
tumours arising from IL-4 R( +) mucosa agrees with studies
of human squamous and adenocarcinomas of the lung
(Tungekar et al., 1991) and adenocarcinomas of the breast
(Mat et al., 1990).
In lung cancers, Tungekar and colleagues (1991), demon-
strated a selective distribution among tumour types sugges-
ting that IL-4 receptors are associated with a particular
differentiation pathway. Since IL-4 has inhibitory effects on
some tumour cell lines, (Tepper et al., 1989) loss of IL-4
receptor may be associated with escape from a negative
regulatory effect and tumour progression.
It is also known that IL-4 possesses the ability to upreg-
ulate both class I and II MHC gene expression in a variety of
macrophage cell types (Stuart et al., 1988). Although it is not
known whether it has a similar effect on malignant epithelial
cells, this will be important to ascertain since such activity is
thought to be involved in modulating the host immune res-
ponse against the tumour.
Although the role of IL-4R is not known in epithelial cells
it may be related to transport of immunoglobulins since IL-4
increased the expression of the epithelial receptor for poly-
meric Ig on a colon cell line. This may provide a pathway for
integrating local immune responses, with IL-4 released from
T-cells modulating immunoglobulin transport. Thus loss of
IL-4R may be related to immunological escape mechanisms
during tumour progression.
Binding experiments on human colon carcinoma cells
ble I
Tumour differentiation and
Antibody staining results
EGFR EGFR
Tumour differentiation IL-4r ( +) IL-4r (-) (+) (-)
Well differentiated n = 18 17 1 9 9
Moderately differentiated n = 22 22 0 12 10
Poorly differentiated n= 5 1 4 2 3
Table II
Tumour types and antibody staining results
IL-4r( +) IL-4r( +) IL-4r( -) IL-4r( -)
Histological type EGFR (+) EGFR (-) EGFR (+) EGFR (-)
ADC, n =44 20 20 1 3
SQC, n=I 0 0 1 0
Adenomas n= 15 9 6 0 0
Table III
Lymph node metastases related to the
staining results of the primary tumours
Tumour progression IL-4r ( + ) IL-4r (-) EGFR ( + )EGFR (-)
LN metastases present n = 25 22 3 18 7
LN metastases absent n = 20 18 2 5 15IL-4 AND EGF RECEPTOR EXPRESSION IN COLORECTAL TUMOURS 715
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Figure 2 Graphic illustration of the correlation between EGFR
expression and lymph node involvement by tumour. This figure
shows that of the 25 colorectal tumours in which lymph node
secondary spread was evident 18 cases were EGFR positive. This
contrasts with only 5 of 20 primary tumours being EGFR
positive when there was no evidence of metastases in lymph
nodes.
(CACO-2) demonstrated the presence of EGFR on the
basolateral and apical side of the monolayers (ratio 2.5/1)
(Hidalgo et al., 1989). On colorectal cancer specimens a
decrease in EGF binding along the crypt-villous axis was also
seen suggesting a loss of receptors with increasing cell
differentiation (Gallo-Payet & Hugon, 1985).
Recent studies (Coffey et al., 1986; Hanauste et al., 1987)
in human colon carcinoma cell lines have confirmed that
malignant cells secrete several growth factors, including
TGF-a/EGF, TGF-P, suggesting that these molecules may
function in an autocrine fashion (Sporn & Todaro, 1980)
playing a contributory role in regulating cell growth. It was
also shown that a monoclonal antibody against TGF-x/EGF
receptor can suppress in vitro tumour growth of a colon
carcinoma cell line (Rodeck et al., 1987).
Expression by both normal colon and neoplastic cells of
high affinity EGF receptors was confirmed by immuno-
precipitation (Murthy et al., 1989; Anzano et al., 1989).
However, expression of these receptors was not a constant
property of malignant cells and failure of receptor detection
or down-regulation has been described in other studies
(Coffey et al., 1987; Rothbauer et al., 1989).
Our results show that expression of EGFR correlates
strongly with tumour progression. Since the latter is related
to prognosis, EGFR1 positivity might be a reliable indicator
of tumour behaviour in colon cancers.
Similar observations have been made in a variety of
tumours such as lung, breast, bladder, ovary and cervix
(Liberman et al., 1984; Berger et al., 1987; Gullick et al.,
1986; Veale et al., 1989; Perez et al., 1984). For breast and
bladder carcinomas a strong correlation has been shown with
pathological stage, relapse and survival (Neal et al., 1989;
Harris et al., 1988; Nicholson et al., 1989; Sainsburry et al.,
1987).
Overall accumulated data provide evidence that over-
production of a positive growth factor (TGF-a/EGF), with
simultaneous lack of responsiveness to a negative one (such
as TGF-P) could influence and upregulate the proliferation of
colon carcinoma cells. Although such an influence may be a
necessary prerequisite, growth regulatory mechanisms other
than those mediated through TGF-a/EGF may also play an
important role in colon cell growth (Lane & Benchimol,
1990; Rodrigues et al., 1990; Vogelstein et al., 1988; Harris,
1990).
Dr L. Kaklamanis is a fellow of the 'Maria-Pantelis Lemos Founda-
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